TY  - JOUR
TI  - The role of circulating tumor DNA (ctDNA) in urothelial cancers
AU  - Aragon-Ching, Jeanny B.
PY  - 2025
JO  - Exploration of Targeted Anti-tumor Therapy
VL  - 6
SP  - 1002317
DO  - 10.37349/etat.2025.1002317
UR  - https://www.explorationpub.com/Journals/etat/Article/1002317
AB  - The role of circulating tumor DNA (ctDNA) in urothelial cancers is a rapidly evolving area of research. Urothelial cancer is the most common subtype of bladder cancer, and biomarkers that predict response or prognosticate outcomes have been long sought after. Tumor-informed ctDNA assays have been utilized in several other cancers and increasingly used in both muscle invasive bladder cancer (MIBC) and metastatic urothelial cancer (mUC) to inform treatment decision-making. While a universal consensus on ctDNA testing has not been fully defined and discussed herein, understanding its benefits and limitations is important to help guide the practical application in the clinic.
ER  -